Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to market, The Wall Street Journal said.

Medical conditions can limit which weight loss pills work safely for you. For example, you should avoid phentermine if you have severe anxiety or hyperthyroidism. Nadler emphasizes the importance of taking anti-obesity medication only under the supervision of a health care professional.